WORCESTER, Mass., Nov. 16, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has made three podium presentations and one poster presentation at the 13th Latin-American Diabetes Congress and the 7th Cuban Diabetes Congress (http://www.alad2007.com) in Havana, Cuba, November 12-16, 2007.
The first podium presentation related to the Company's proprietary metformin chewing gum. Dr. David Saldarreaga made the poster presentation of a paper entitled, "Metformin Gum: An Alternative Method for Delivery of Biguanides." The paper is co-authored by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre and Jeannette Saaverdra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador.
Two podium presentations related to the Company's proprietary oral insulin spray product, Generex Oral-lyn(tm). The presentations were most recently made at the 11th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meeting (CDA/CSEM) and at the 7th Annual Diabetes Technology Meeting.
Dr. Jaime-Aguirre made an oral presentation of a paper entitled, "Pre-prandial S.C. Regular Insulin Versus Prandial Oral-lyn in Type-1 DM Subjects Maintained in Basal S.C. Twice Daily Isophane Insulin (NPH)." The paper is co-authored by Doctors Marco Guevara-Aguirre and Jeannette Saaverdra all of the Institute of Endocrinology IEMYR, Quito, Ecuador.
Dr. Marco Guevara-Aguirre made an oral presentation of a paper entitled, "Oral Insulin at Lunchtime in Juvenile Type-1 DM Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin." The paper is co-authored by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre and Jeannette Saaverdra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, and Gerald Bernstein, the Company's Vice-President for Medical Affairs.
The poster presentation also related to the Company's proprietary oral insulin spray product, Generex Oral-lyn(tm): "Near Normalization of Metabolic Control in Type-1 DM Using Conventional Insulin Therapy and a 13-Point Method Designed to Enhance Compliance," by Doctors Marco Guevara-Aguirre, Jamie Guevara-Aguirre and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, and Gerald Bernstein, the Company's Vice-President for Medical Affairs.
About Generex
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical development around the world. In June 2007 the Company announced that patient dosing in a global Phase III clinical trial of Generex Oral-lyn(tm) will commence before year-end. For more information, visit the Generex website at http://www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.